Cannabinoid hyperemesis syndrome

Current Drug Abuse Reviews

Volumn 4, Issue 4, 2011, Pages 241-249

  Galli, Jonathan A ^a   Sawaya, Ronald Andari ^a   Friedenberg, Frank K ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabinoid hyperemesis syndrome; Cannabis; Marijuana; Nausea; Vomiting

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABIDIOL; CANNABIGEROL; CANNABINOID; CANNABINOID RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DRONABINOL; ENDOCANNABINOID; HISTAMINE H1 RECEPTOR ANTAGONIST; NABILONE; NARCOTIC ANALGESIC AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ARTICLE; BRAIN REGION; CANNABINOID HYPEREMESIS SYNDROME; CANNABIS ADDICTION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DELAYED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FLUID RESUSCITATION; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MOLECULAR PATHOLOGY; NAUSEA AND VOMITING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRIORITY JOURNAL; SIDE EFFECT; STOMACH EMPTYING; STOMACH RADIOGRAPHY; TEMPERATURE DEPENDENCE; VOMITING;

EID: 83455220556     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/1874473711104040241     Document Type: Article

References (78)

1. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health, 2009. ICPSR29621- v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor], 2010-11-16. doi: 10.3886/ICPSR29621.
2. Foley JD. Adolescent use and misuse of marijuana. Adolesc Med Clin 2006; 17: 319-34.
3. European Monitoring Centre of Drugs and Drug Addiction. Annual report 2006: the state of the drugs problem in Europe. Report No: 92-9168-266-7. Office for Official Publications of the European Communities, Luxembourg, 2006.
4. Compton WM, Grant BF, Colliver JD, et al. Prevalence of marijuana use disorder in the United States: 1991-1992 and 2001-2002. JAMA 2004; 291: 2214-21.
5. Stinson FS, Ruan WJ, Pickering R, et al. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med 2006; 36: 1447-60.
6. Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis use. Gut 2004; 53: 1566-70.
7. Howlett AC, Johnson MR, Melvin LS, et al. Nonclassical Cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. Mol Pharmacol 1988; 33: 297-302.
8. Iverson L. Cannabis and the brain. Brain 2003; 126: 1252-70.
9. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008; 57: 1140-55.
10. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74: 129-80.
11. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem 1999; 6: 635-64.
12. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005; 129: 437-53.
13. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB(2) receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008; 153: 263-70.
14. Mathison R, Ho W, Pittman QJ, et al. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharidetreated rats. Br J Pharmacol 2004; 142: 1247-54.
15. Duncan M, Davison JS, Sharkey KA. Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22: 667-83.
16. Cadas H, di Tomaso E, Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursors, N-arachidonoyl phosphatidylethanolamine, in rat brains. J Neurosci 1997; 17: 1226-42.
17. DiMarzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686-91.
18. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298: 7-14.
19. Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995; 18: 1138-41.
20. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-60.
21. Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9 tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 1983; 34: 352-63.
22. Kreuz DS, Axelrod J. Delta-9-tetrahydrocannabinol: localization in body fat. Science 1973; 179: 391-3.
23. Gunasekaran N, Long LE, Dawson BL, et al. Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br J Pharmacol 2009; 158: 1330-7.
24. Harvey DJ, Brown NK. Comparative in vitro metabolism of the cannabinoids. Pharmacol Biochem Behav 1991; 40: 533-40.
25. Perez-Reyes M, Timmons M, Lipton M, et al. Intravenous injection in man of delta-9-tetrahydro-cannabinol and 11-OH-delta-9- tetrahydrocannabinol. Science 1972; 177: 633-5.
26. Burstein SH. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 1999; 82: 87-96.
27. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002; 42: 11-19.
28. Russo EB, Burnett A, Hall B, et al. Agonistic properties of Cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037-43.
29. Hayakawa K, Mishima K, Hazekawa M, et al. Cannabidiol potentiates pharmacologic effects of Δ 9 -tetrahydrocannabinol via CB1 receptordependent mechanism. Brain Res 2008; 1188: 157-64.
30. Parker LA, Kwiatkowska M, Burton P, et al. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus(house musk shrew). Psychopharmacology 2004; 171: 156-61.
31. Kwiatkowska M, Parker LA, Burton P, et al. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatininduced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 2004; 174: 254-9.
32. Cascio MG, Gauson LA, Stevenson LA, et al. Evidence that the plant cannabinoid cannabigerol is a highly potent alpha 2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist. Br J Pharmacol 2010; 159: 129-41.
33. Rock EM, Goodwin JM, Limebeer CL, et al. Interaction between nonpsychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 2011; [Epub ahead of print].
34. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761-75.
35. Darmani NA. The potent emetogenic effects of the endocannabinoid, 2- AG (2-arachidonoylglycerol), are blocked by delta (9)- tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 2002; 300: 34-42.
36. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001; 121: 767-74.
37. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer 2003; 11: 137-43.
38. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73-100.
39. Cota D, Steiner MA, Marsicano G, et al. Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitaryadrenal axis function. Endocrinology 2007; 148: 1574-81.
40. Lehmann A, Blackshaw LA, Brandon L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxation and reflux in dogs. Gastroenterology 2002; 123: 1129-34.
41. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 2006; 148: 191-99.
42. Esfandyari T, Camilleri M, Busciglio I, et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007; 293: 137-45.
43. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001; 48: 859-67.
44. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, et al. Delta9- tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 1999; 371: 187-96.
45. Izzo AA, Mascolo N, Capasso R, et al. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 221-3.
46. McCallum RW, Soykan I, Sridhar KR, et al. Delta-9- tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13: 77-80.
47. Esfandyari T, Camilleri M, Ferber I, et al. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006; 18: 831-8.
48. Abalo R, Cabezos PA, Lopez-Miranda V, et al. Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55, 212-2 in the rat. Neurogastroenterol Motil 2009; 21: 1002-80.
49. Abalo R, Cabezos PA, Vera G, et al. Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent administration in the rat: role of CB1 receptors. Neurogastroenterol Motil 2011; 23; 457-77.
50. Parkman HP, Fass R, Foxx-Orenstein AE. Treatment of patients with diabetic gastroparesis. Gastroenterol Hepatol 2010; 6: 1-16.
51. Roche E, Foster PN. Cannabinoid hyperemesis: not just a problem in Adelaide Hills. Gut 2005; 54: 731.
52. Singh E, Coyle W. Cannabinoid hyperemesis. Am J Gastroenterol 2008; 103: 1048-9.
53. Wallace D, Martin AL, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water. Aust Psychiatry. 2007; 15: 156-8.
54. Budhraja V, Narang T, Slaiman A. Cannabinoid hyperemesis syndrome: cyclic vomiting, chronic cannabis use and compulsive bathing. Pract Gastroeneterol 2008; 32: 79-80.
55. Chang YH, Windish D. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc 2009; 84: 76-78.
56. Sannarangappa V, Tan C. Cannabinoid hyperemesis. Intern Med J 2009; 39: 777-8.
57. Sontineni SP, Chaudhary S, Sontineni V, et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an under recognized manifestation of chronic cannabis abuse. World J Gastroenterol 2009; 15: 1264-6.
58. Watts M. Cannabinoid hyperemesis presenting to a New Zealand hospital. N Z Med J 2009; 122: 116-8.
59. Donnino MW, Cocchi MN, Miller J, et al. Cannabinoid hyperemesis: a case series. J Emerg Med 2009; 40: 63-6.
60. Miller JB, Walsh M, Patel PA, et al. Pediatric cannabinoid hyperemesis: two cases. Pediatr Emerg Care 2010; 26: 919-20.
61. Patterson DA, Smith E, Monahan M, et al. Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation. J Am Board Fam Med 2010; 23; 790-3.
62. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci 2010; 55: 3113-9.
63. Quigley E, Hasler W, Parkman H. AGA Technical review on nausea and vomiting. Gastroenterology 2001; 120: 263-86.
64. Abell TL, Kim CH, Malagelada JR. Idiopathic cyclic nausea and vomiting-a disorder of gastrointestinal motility. Mayo Clin Proc 1988; 63: 1169-75.
65. Namin F, Patel J, Lin Z, Sarosiek I, Foran P, Esmaeili P, et al. Clinical, psychiatric and manometric profile of cyclic vomiting syndrome in adults and response to tricyclic therapy. Neurogastroenterol Motil 2007; 19: 196-202.
66. Hejazi RA, Reddymasu SC, Namin F, Lavenbarg T, Foran P, McCallum RW. Efficacy of tricyclic antidepressant therapy in adults with cyclic vomiting syndrome: a two-year follow-up study. J Clin Gastroenterol 2010; 44: 18-21.
67. Tack J, Talley N, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466-79.
68. Schmid SM, Lapaire O, Huang DJ, et al. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy. Arch Gynecol Obstet 2010; [Epub ahead of print].
69. Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med 2009; 10: 654-62.
70. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther 2003; 74: 102-12.
71. Chepyala P, Olden KW. Cyclic vomiting and compulsive bathing with chronic cannabis abuse. Clin Gastroenterol Hepatol 2008; 6: 710-12.
72. Darmani NA. Cannabinoid-induced hyperemesis: A conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals 2010; 3: 2163-77.
73. Budney AJ, Roffman R, Stephens RS, et al. Marijuana dependence and its treatment. Addict Sci Clin Pract 2007; 4: 4-16.
74. Budhraja V. Confirming the diagnosis of cannabinoid hyperemesis syndrome. Mayo Clin Proc 2009; 84: 483.
75. Byrne A, Hallinan R, Wodak A. Cannabis hyperemesis causation questioned. Gut 2006; 55: 132.
76. Watson SJ, Benson JA, Joy JE. Marijuana and Medicine: assessing the science base: a summary of the 1999 Institute of Medicine Report. Arch Gen Psychiatry 2000; 57: 547-52.
77. Topol EJ, Bhatt DL, et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010; 9740: 517-23.
78. Fremming BA, Boyd ST. Taranabant, a novel cannabinoid type 1 receptor inverse agonist. Curr Opin Investig Drugs. 2008; 9: 1116-29.